Trelegy denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for trelegy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny Trelegy Ellipta as Experimental

An "experimental or investigational" denial for Trelegy Ellipta is unusual, because Trelegy is FDA-approved for both COPD and asthma in adults. When this denial appears, it almost always means one of the following: (1) the specific indication documented in the claim does not match an FDA-approved use (for example, the drug is being used in a pediatric population, a different disease, or at a dosing regimen outside the label), (2) the claim was submitted with an ICD-10 code that Cigna does not map to an approved indication in its coverage policy, or (3) there is a documentation error that caused an automated experimental classification.

## Why This Denial Is Appealable

Because Trelegy is FDA-approved for COPD and for asthma in adults, a denial on experimental grounds for an on-label use is almost certainly wrongly classified. Correcting the clinical record or the indication coding is often sufficient to reverse this denial at the internal-appeal stage. If the use is genuinely off-label, you may still appeal by demonstrating support in recognized medical compendia or specialty guidelines. ACA §2719 and ERISA §503 guarantee internal and external review rights.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial; attach the FDA approval documentation and a prescriber letter explicitly tying the prescription to an approved indication.
• External review: Available after internal exhaustion; the IRO must assess whether the treatment meets accepted clinical standards, not just the insurer's internal classification.
• Expedited option: Request immediately if you are without a COPD or asthma controller and your respiratory health is at risk.

## Documentation to Gather

1. FDA approval confirmation — the current FDA-approved prescribing information for Trelegy from DailyMed, confirming the approved indications, to attach directly to your appeal letter. 2. Indication-coding review — have the prescriber's billing office confirm that the ICD-10 code on the claim maps correctly to the FDA-approved indication; submit a corrected claim if there was a coding error. 3. Prescriber medical-necessity letter — a letter from the treating physician stating the diagnosis, the specific FDA-approved indication being treated, and why Trelegy is the appropriate agent. 4. Diagnosis and severity documentation — pulmonology or primary care chart notes confirming the diagnosis (COPD, asthma) and disease severity. 5. Applicable guideline reference — reference to the relevant guideline organization (e.g., GOLD for COPD, GINA for asthma) endorsing triple inhaler therapy for the patient's disease stage.

## Criteria-Mapping Structure

Directly rebut each basis for the experimental classification:

| Experimental Denial Basis | Rebuttal Evidence | |---|---| | Not FDA-approved | FDA label from DailyMed confirming approved indication | | Indication coding mismatch | Corrected ICD-10 code + prescriber confirmation | | No recognized guideline support | Guideline organization citation from prescriber letter |

Review Cigna's current coverage policy for Trelegy and the FDA-approved prescribing information to ensure your appeal addresses every stated basis for the experimental classification.